When was Vivodyne founded?

Vivodyne was founded in 2021 and raised its 1st funding round within a year of its incorporation.

Where is Vivodyne located?

Vivodyne is headquartered in Philadelphia, United States.

Which legal entities is Vivodyne associated with?

Vivodyne is associated with VIVODYNE, INC..

Is Vivodyne a funded company?

Vivodyne is a funded company, having raised a total of $80M across 3 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Mar 11, 2021.

How much is Vivodyne worth?

The latest valuation of Vivodyne is $***** as of Dec 02, 2022.

When was the latest funding round of Vivodyne?

Vivodyne's latest funding was a $***** Series A round on May 29, 2025, with participation from 8 investors.

Where does Vivodyne rank among its competitors?

Vivodyne ranks 9th amongst 47 active competitors, of which 23 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Emulate, which secured $493K in Sep, 2025.

Who are the top competitors of Vivodyne?

Vivodyne's top competitors include Emulate, CN Bio and Hesperos. Among them, Emulate secured the most recent funding round in September, 2025.

Vivodyne - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of AI-based platform for lab-grown human tissues. The company's platform culture human tissue models for drug discovery and utilizes single-cell 4D phenomics with an integrated confocal microscope. Also, has an automated robotic system that discovers drugs and cellular therapies.

Website: www.vivodyne.com/
Social
Email ID: *****@vivodyne.com

Key Metrics

Founded Year

2021

Location

Philadelphia, United States

Stage

Series A

Total Funding

$80M in 3 rounds

Latest Funding Round

Series A, May 29, 2025, $*****

Post Money Valuation

$***** as on Dec 02, 2022

Investors

Khosla Ventures & 7 more

Ranked

9^th among 47 active competitors

Similar Companies

Emulate & 47 more

View Vivodyne's full profile

Vivodyne is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
VIVODYNE, INC. CIN: 4157677 , United States, Active	Nov 16, 2020	-	-	-

Vivodyne has raised a total funding of $80M over 3 rounds. Its first funding round was on Mar 11, 2021. Its latest funding round was a Series A round on May 29, 2025 for $*****. 8 investors participated in its latest round. Vivodyne has 8 institutional investors.

Here is the list of recent funding rounds of Vivodyne:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 29, 2025	7459691	Series A	6074507	5306847	3515149	4256109
Nov 22, 2023	6651119	Seed	6892624	1687163	9169668	Kairos Ventures & 3 more
Mar 11, 2021	8565004	Seed	4950724	2925122	7752183	Kairos Ventures

Access funding benchmarks and valuations. Sign up today!

View details of Vivodyne's funding rounds and investors

The founders of Vivodyne is Dan Huh.

Here are the details of Vivodyne's key team members:

Dan Huh: Co-Founder of Vivodyne.
Contact Info: 1 email address

View details of Vivodyne's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Vivodyne include Emulate, CN Bio and Hesperos. Here is the list of Top 10 competitors of Vivodyne, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Emulate 2013, Boston (United States), Series E	Developer of in vitro models for drug development	$204M	ND Capital, Cedars Sinai & 25 others	58/100
2nd	CN Bio 2009, Cambridge (United Kingdom), Series B	Develops organ-on-a-chip platforms for drug discovery	$71.2M	CITIC, Zray Management & 13 others	58/100
3rd	Hesperos 2015, Orlando (United States), Funding Raised	Developer of organ-on-a-chip solutions for preclinical testing	-	HHS, NCATS	53/100
4th	Mimetas 2013, Leiden (Netherlands), Series B	Develops microfluidics-based organ-on-a-chip tissue models	$28.9M	Zeeuws Investerings Fonds, Oost NL & 13 others	45/100
5th	Obatala Sciences 2017, New Orleans (United States), Series A	Provider of research enabling products and services to research centers	$3.54M	Ochsner, être & 9 others	43/100
6th	Cellbox Labs 2020, Riga (Latvia), Seed	Provider of organ-on-chip platform for drug discovery and development	$1.01M	Buildit, European Innovation Council & 5 others	43/100
7th	Numa Biosciences 2007, Woodinville (United States), Acquired	Developer of platform for generating small segments of human tissues and organs in microfluidic chips	$10.7M	SeaChange Fund, Vertical Venture Partners ... & 3 others	43/100
8th	Okomera 2020, Paris (France), Seed	Developer of a device for in vitro cancer testing using a microfluidic chip	$11.2M	Resonance, Polytechnique Ventures & 4 others	42/100
9th	Vivodyne 2021, Philadelphia (United States), Series A	Developer of AI-based platform for lab-grown human tissues	$80M	MBX Capital, Lingotto & 6 others	41/100
10th	NETRI 2018, Lyon (France), Series A	Developer of microfluidic devices for industrial applications	$14M	Bpifrance, Netangels & 4 others	40/100